↑ 薬物リストへ　← 戻る

Mor202    (DrugBank: -)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
222一次性ネフローゼ症候群8

222. 一次性ネフローゼ症候群　［臨床試験数：234，薬物数：241（DrugBank：78），標的遺伝子数：59，標的パスウェイ数：185］
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 234 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2020-002985-15-DE
(EUCTR)		21/12/202031/08/2020Open-label, 2-arm, multicenter clinical trial to assess safety, efficacy and PK/PD of MOR202 in anti-PLA2R antibody positive membranous nephropathy (aMN)A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) - NewPLACE Anti-PLA2R antibody positive membranous nephropathy (aMN)
MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: MOR202
INN or Proposed INN: not yet assigned
Other descriptive name: MOR03087		MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		22Phase 2Taiwan;Greece;Australia;Russian Federation;Georgia;Germany;United Kingdom;Korea, Republic of
2EUCTR2020-002985-15-GR
(EUCTR)		22/10/202011/09/2020Open-label, 2-arm, multicenter clinical trial to assess safety, efficacy and PK/PD of MOR202 in anti-PLA2R antibody positive membranous nephropathy (aMN)A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) - NewPLACE Anti-PLA2R antibody positive membranous nephropathy (aMN)
MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: MOR202
INN or Proposed INN: not yet assigned
Other descriptive name: MOR03087		MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		22Phase 2Taiwan;Greece;Australia;Russian Federation;Georgia;Germany;United Kingdom;Korea, Republic of
3EUCTR2020-002985-15-GB
(EUCTR)		12/10/202025/08/2020Open-label, 2-arm, multicenter clinical trial to assess safety, efficacy and PK/PD of MOR202 in anti-PLA2R antibody positive membranous nephropathy (aMN)A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) - NewPLACE Anti-PLA2R antibody positive membranous nephropathy (aMN)
MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: MOR202
INN or Proposed INN: not yet assigned
Other descriptive name: MOR03087		MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		22Phase 2Taiwan;Greece;Australia;Russian Federation;Georgia;Germany;United Kingdom;Korea, Republic of
4EUCTR2019-000780-24-ES
(EUCTR)		25/10/201926/07/2019Open Label Clinical Trial to assess Safety and Efficacy of MOR202 in Membranous NephropathyA Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE Primary (anti-PLA2R antibody positive) Membranous Nephropathy
MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Body processes [G] - Immune system processes [G12]		Product Name: MOR202
Product Code: MOR202
INN or Proposed INN: No INN assigned yet
Other descriptive name: MOR03087		MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		30Phase 1;Phase 2France;United States;European Union;Spain;Netherlands
5NCT04145440
(ClinicalTrials.gov)		October 15, 201918/10/2019Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)Glomerulonephritis, Membranous;antiPLA2R PositiveDrug: MOR202MorphoSys AGNULLRecruiting18 Years80 YearsAll30Phase 1;Phase 2United States;Belgium;France;Italy;Netherlands;Spain
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2019-000780-24-IT
(EUCTR)		08/10/201922/01/2020Open Label Clinical Trial to assess Safety and Efficacy of MOR202 in Membranous NephropathyA Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE Primary (anti-PLA2R antibody positive) Membranous Nephropathy
MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Body processes [G] - Immune system processes [G12]		Product Name: MOR202
Product Code: MOR202
INN or Proposed INN: No INN assigned yet
Other descriptive name: MOR03087		MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		30Phase 1;Phase 2France;United States;European Union;Spain;Netherlands;Italy
7EUCTR2019-000780-24-NL
(EUCTR)		24/09/201903/07/2019Open Label Clinical Trial to assess Safety and Efficacy of MOR202 in Membranous NephropathyA Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE - M-PLACE Primary (anti-PLA2R antibody positive) Membranous Nephropathy
MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Body processes [G] - Immune system processes [G12]		Product Name: MOR202
Product Code: MOR202
INN or Proposed INN: No INN assigned yet
Other descriptive name: MOR03087		MorphoSys AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		30Phase 1;Phase 2France;United States;European Union;Spain;Australia;Netherlands;Italy;Korea, Republic of
8EUCTR2019-000780-24-FR
(EUCTR)		23/09/201915/10/2019Open Label Clinical Trial to assess Safety and Efficacy of MOR202 in Membranous NephropathyA Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE Primary (anti-PLA2R antibody positive) Membranous Nephropathy
MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857 ;Therapeutic area: Body processes [G] - Immune system processes [G12]		MorphoSys AGNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		30Phase 1;Phase 2United States;France;European Union;Spain;Netherlands

先頭へ